What is TG137?
permanent interstitial brachy for prostate cancer
issue with edema
target volume delineation depends a lot on time of imaging after implant because of edema from surgery
common isotopes for permanent prostate LDR
I-125
Pd-103
what does TG-137 recommend for imaging for post-implant evaluation?
2-3 mm slice axial CT images
are seeds expected to move over time?
Yes, due to swelling of prostate and after swelling has gone down
Is MRI or CT more useful?
soft tissue better with MRI
seeds better with CT
when should imaging for dosimetry evaluation be done?
common doses
125-145 Gy
I-125 dose rate
7 cGy/h
common OARs
urethra, rectum
planning targets and constraints
CTV: V100% > 95%
CTV: V150% < 50%
Rectum: D2cc < Rx, D0.1cc < 150%
Urethrea: D10<150%, D30< 130%
what are some biophysical models that are used for prostate implants?
-analytic expression of BED based on linear-quadratic cell inactivation model (Dale BED)
-EUD
-TCP determined by Poisson probability of inactivating all tumour cells with the average surviving cells calculated according to Dale’s BED.
More advance models taking into account cell repopulation and different temporal patterns of dose delivery have been developed
what biophysical model is recommended by TG-137?
Dale BED model
what parameter values are recommended in Dale BED model?
alpha = 0.15 Gy-1, beta = 0.05 Gy-2, alpha/beta = 3.0 Gy, Tp = 42 days (potential doubling time) and repair half-life of 0.27 hours
what do the biophysics models ignore?
heterogeneity corrections
interseed shielding
where should PDR patients be careful?
around children, pregnant women, urinating, intercourse, airport and funeal should be detectors
Using CT/MR/US
-hard to delineate prostate with CT (bladder and prostate often mixed together if overlap) i.e. not great base and apex definition
main recommendations from TG137
-postimplant evaluation should be done at optimal time for specific radionuclides
0encourage use of a radiobiological model with a specific set of parameters to facilitate relative comparions of treatment plans reported by different institutions using different loading patterns or radionuclides
sources used in LDR
125I
103Pd
131Cs
staging of prostate cancer
low risk: stage < 2B, gleason < 6, PSA < 10
intermediate: stage < 2b, gelason = 7, PSA within 10 and 20
high risk: stage = 2c, gleason >8, PSA >20
options other than brachy for early stage prostate cancer
3 ways cure rates in prostate brachy are measured
coverage index
CI = 100(V100-Vt)/Vt where Vt is target volume and V100 is volume that gets 100 % of prescription dose
why do we want D90> 140 Gy?